Ipca Laboratories Ltd Share Price
As on 01 December 2025 at 04:43 IST
Ipca Laboratories Q1 FY26 Results:
Net profit after tax for the period increased 17% to ₹233 crores in Q1 FY26, from ₹199 crores in Q1 FY25. Total income for the quarter increased 11% year-on-year to ₹2,342 crores from ₹2,113 crores.
About Ipca Laboratories Ltd
Ipca Laboratories Ltd., established in the year 1949 and headquartered in Mumbai, is a prominent Indian pharmaceutical multinational. The company has evolved into a major global player, specializing in the manufacturing and distribution of active pharmaceutical ingredients (APIs) and formulations. Their comprehensive product portfolio encompasses generic drugs, OTC medications, and specialty pharmaceuticals. With a commitment to quality, Ipca Laboratories Ltd. has built a strong reputation in both Indian and international markets. Over its rich journey, the company has demonstrated consistent growth and expansion, cementing its position in the pharmaceutical sector. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
7.55%
Over 6 Months
-4.36%
Over 1 Year
-8.67%
Over 3 Years
59.04%
Ipca Laboratories Ltd Summary
Close ₹1,396
Open ₹1,407
High ₹1,417
Low ₹1,388.50
Volume 1,00,045
Net Turnover (in Cr) ₹14.03
52Wk High ₹1,755.90
52Wk Low ₹1,168.20
52Wk High / Low
1,168.20
1,755.90
Ipca Laboratories Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹35,417.11
EPS (TTM) 38.18
Book Value (BV) 291.98
Div. Yield 0.29 %
P/E (TTM) 45.97
Price/Book Value 4.77
Delivery % 37.32 %
Face Value 1
Key Ratios
PE Ratio 58.53
PB Ratio 5.53
EV to Sales 5.81
PEG Ratio 2.58
ROA 8.28
ROE 12.39
Debt-Equity 0.16
Net Profit Margin 12.28
Operating Profit Margin 23.62
Ipca Laboratories Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 9,032.39 | 7,829.81 | 6,369.94 | 5,896.36 | 5,482.83 |
| Total Expenses | 7,696.20 | 6,879.39 | 5,624.65 | 4,760.64 | 4,093.85 |
| Profit Before Tax | 1,131.14 | 842.67 | 745.29 | 1,135.72 | 1,388.98 |
| Profit After Tax | 787.53 | 529.21 | 491.93 | 910.95 | 1,148.84 |
| Operating Profit After Depreciation | 1,421.12 | 1,088.69 | 790.83 | 1,143.41 | 1,398.02 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 4,272.15 | 4,572.69 | 2,769.64 | 2,414.77 | 2,123.59 |
| Total Non Current Assets | 5,793.51 | 5,562.38 | 3,437.16 | 3,176.82 | 2,631.40 |
| Total Current Assets | 5,967.04 | 5,538.90 | 5,189.27 | 4,446.71 | 3,436.96 |
| Total Assets | 11,760.55 | 11,101.28 | 8,626.43 | 7,623.53 | 6,068.36 |
| Total Shareholder's Fund | 6,948.45 | 6,332.19 | 5,842.02 | 5,464.84 | 4,701.65 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 1,321.32 | 944.65 | 805.81 | 856.07 | 1,090.13 |
| Net Cash Used In Investing Activities | -869.50 | -1,215.29 | -725 | -850.93 | -520.69 |
| Net Cash Used In Financing Activities | -282.98 | -552.55 | 507.24 | 426.78 | -305.82 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 6,749.21 | 6,277.75 | 5,925.81 | 5,491.22 | 5,201.40 |
| Total Expenses | 5,467.90 | 5,322.23 | 5,175.32 | 4,417.11 | 3,821.44 |
| Profit Before Tax | 999.77 | 822.16 | 750.49 | 1,074.11 | 1,379.96 |
| Profit After Tax | 650.76 | 530.41 | 505.70 | 860.37 | 1,140.77 |
| Operating Profit After Depreciation | 1,344.35 | 1,076.19 | 794.41 | 1,081.35 | 1,388.10 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 2,542.31 | 2,533.17 | 2,487.37 | 2,156.87 | 1,869.75 |
| Total Non Current Assets | 5,290.98 | 5,149.38 | 3,571.82 | 3,213.98 | 2,732.34 |
| Total Current Assets | 3,779.94 | 3,509.89 | 4,875.15 | 4,224.46 | 3,277.79 |
| Total Assets | 9,070.92 | 8,659.27 | 8,446.97 | 7,438.44 | 6,010.13 |
| Total Shareholder's Fund | 6,891.62 | 6,348.71 | 5,877.30 | 5,475.76 | 4,752.72 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 1,374.07 | 830.51 | 762.29 | 831.72 | 1,096.06 |
| Net Cash Used In Investing Activities | -738.81 | -1,355.18 | -709.61 | -811.85 | -559.56 |
| Net Cash Used In Financing Activities | -428.44 | -464.88 | 506.38 | 426.04 | -307.38 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 2,556.50 | 2,308.85 | 2,246.69 | 2,245.37 | 2,354.90 |
| Total Expenses | 2,011.58 | 1,892.43 | 1,817.83 | 1,782.29 | 1,913.42 |
| Profit Before Tax | 391.58 | 330.51 | 128 | 367.92 | 344.83 |
| Profit After Tax | 283.50 | 234.42 | 65.78 | 277.33 | 245.44 |
| Operating Profit after Depreciation | 572.78 | 449.08 | 454.68 | 483.19 | 467.74 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 1,930.32 | 1,746.90 | 1,638.44 | 1,662.68 | 1,810.94 |
| Total Expenses | 1,465.61 | 1,339.98 | 1,279.85 | 1,251.59 | 1,408.83 |
| Profit Before Tax | 408.31 | 356.75 | 17.15 | 355.52 | 339.21 |
| Profit After Tax | 304.74 | 262.04 | -65.05 | 267.56 | 244.12 |
| Operating Profit after Depreciation | 486.63 | 431.94 | 380.08 | 428.50 | 419.11 |
Ipca Laboratories Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 1,384
S2 1,372
S3 1,355.50
Pivot 1,400.50
R1 1,412.50
R2 1,429
R3 1,441
Moving Average
20 SMA 1,371.68
50 SMA 1,343.63
100 SMA 1,377.60
200 SMA 1,389.39
Ipca Laboratories Ltd Corporate Actions
Ipca Laboratories Ltd
₹2.0/Share
Announcement Date 05 Aug 2025
Record Date 05 Aug 2025
Div Yield 200%
Ipca Laboratories Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,809.50 | ₹4,34,159.66 |
| Divis Laboratories Ltd | ₹6,489.95 | ₹1,72,287.78 |
| Torrent Pharmaceuticals Ltd | ₹3,735.90 | ₹1,26,434.15 |
| Cipla Ltd | ₹1,524.55 | ₹1,23,148.76 |
| Dr Reddys Laboratories Ltd | ₹1,250.50 | ₹1,04,369.38 |
Ipca Laboratories Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| DSP Midcap Fund | 3.01% |
| Kotak Midcap Fund | 2.53% |
| HDFC Mid Cap Fund | 2.52% |
| DSP Small Cap Fund | 1.75% |
| DSP Large & Mid Cap Fund | 1.50% |
Ipca Laboratories Ltd News
Ipca Laboratories to announce Quarterly Result
On 13 November 2025
18 Oct 2025, 10:40 am
Ipca Laboratories incorporates wholly owned subsidiary in Germany
16 Oct 2025, 02:39 pm
Ipca Laboratories Ltd eases for fifth straight session
Ipca Laboratories Ltd is quoting at Rs 1309.5, down 1.06% on the day as on 13:19 IST on the NSE. The stock tumbled 22.06% in last one year as compared to a 0.11% rally in NIFTY and a 6.5% fall in the Nifty Pharma index.
14 Oct 2025, 01:35 pm
Ipca teams with BioSimilar Sciences PR LLC
To accelerate affordable biologics for treatment of cancer and autoimmune disease
24 Sep 2025, 07:32 pm
Ipca Labs Q1 PAT climbs 21% YoY to Rs 233 cr
Ipca Laboratories reported 21.31% increase in consolidated net profit of Rs 233.31 crore in Q1 FY26 as against Rs 192.24 crore posted in Q1 FY25.
11 Aug 2025, 02:36 pm
Ipca Laboratories Ltd Stock Analysis
- Annual revenue for Ipca Laboratories Ltd increased by 7.51% to ₹6,749.21 crore in FY 2025 from ₹6,277.75 crore in FY 2024.
- Annual Net Profit for Ipca Laboratories Ltd increased by 22.69% to ₹650.76 crore in FY 2025 from ₹530.41 crore in FY 2024.
- Promoter Shareholding in Ipca Laboratories Ltd remains unchanged by 0.00% in the most recent quarter, from 44.72% in June 2025 to 44.72% in September 2025.
- Ipca Laboratories Ltd delivered a 1-year return of -8.67% compared to the Nifty 50, which provided a return of 7.99% as of the last trading session.
- Ipca Laboratories Ltd share price moved up by 1.79% from its previous close of INR ₹1,396. The latest Ipca Laboratories Ltd share price is INR ₹1,421.
- Ipca Laboratories Ltd share price today has been at a low of 1,396 and a high of 1,428.20. Over the past 52 weeks, the Ipca Laboratories Ltd share price has seen a low of 1,168.20 and a high of 1,755.90.
About Ipca Laboratories Ltd
Ipca Laboratories Ltd., established in 1949 and headquartered in Mumbai, is a prominent Indian pharmaceutical multinational. The company has evolved into a major global player, specializing in the manufacturing and distribution of active pharmaceutical ingredients (APIs) and formulations. Their comprehensive product portfolio encompasses generic drugs, OTC medications, and specialty pharmaceuticals.
With a commitment to quality, Ipca has built a strong reputation in both Indian and international markets. Over its rich journey, the company has demonstrated consistent growth and expansion, cementing its position in the pharmaceutical sector.
The promoters of the company include Kaygee Investments Private Limited, with a 21.47% stake. A team of managerial promoters manage the operations of the company. They are -
While Ipca Laboratories may not be the largest in terms of market share or capitalization, it is still highly regarded in the market. The company is known for its innovative solutions and customer-centric approach. The registered office of Ipca Laboratories Ltd. is in Kandivli, Mumbai and the office of the registrar is in Vikhroli, Mumbai.
Ipca Laboratories Ltd. stands out as a major player in the pharmaceutical sector. It has a rich history, a robust product portfolio, and a strong market presence. Its strategic partnerships and efficient management continue to drive the company forward.
The manufacture and distribution of premium APIs is one of Ipca Laboratories' main contributions. The business produces more than 80 APIs, which are utilized in manufacturing different drugs. Since they make up the active ingredients of medications, these APIs are crucial to the pharmaceutical sector.
Ipca Laboratories has also made a significant impact through its formulation business. The company produces a wide range of generic and branded formulations, including tablets and injectables. These products cater to various therapeutic areas, providing effective treatment options for patients. Ipca’s formulations are known for their efficacy and affordability, making them accessible to a broad population.
The company’s focus on research and development (R&D) has further amplified its impact. Ipca Laboratories invests significantly in R&D to develop new and improved pharmaceutical products. This investment has led to the creation of innovative therapies that address unmet medical needs. For example, Ipca’s advancements in antimalarial drugs have played a crucial role in combating malaria, which affects millions of people worldwide. The company’s R&D efforts keep it at the forefront of pharmaceutical innovation. These efforts continuously contribute to the advancement of medical science.
Ipca Laboratories’ commitment to sustainability and corporate social responsibility (CSR) also highlights its impact. The company engages in various CSR initiatives aimed at improving the quality of life in the communities where it operates. These initiatives include healthcare camps and environmental conservation efforts.
The company’s global reach further underscores its impact. Ipca Laboratories exports its products to over 120 countries, which includes highly regulated markets like the United States and Japan. This extensive global presence ensures that high-quality medications are available to patients worldwide. Ipca’s ability to meet international regulatory standards demonstrates its commitment to quality and safety. This reinforces its reputation as a reliable pharmaceutical manufacturer.
Ipca Laboratories has also played a crucial role in supporting the healthcare infrastructure in India. The company collaborates with various healthcare providers and government agencies. This helps improve access to essential medicines. These collaborations have been especially important during public health emergencies like the COVID-19 pandemic. Ipca’s timely supply of critical medications helped manage the crisis.
The financial performance and growth trajectory of Ipca Laboratories are indicative of its impact on the industry. The company has consistently achieved strong revenue growth. This is driven by its robust product portfolio and strategic market expansion. Ipca’s financial stability provides confidence to investors and stakeholders. It also enables the company to continue investing in innovation and growth.
Ipca Laboratories’ impact is also evident in its role as an employer. The company employs thousands of people, contributing to economic development and social stability. Ipca’s focus on employee development and welfare ensures that its workforce is skilled, motivated, and engaged. This commitment to human capital development is essential for the company’s long-term success and sustainability.
With a commitment to quality, Ipca has built a strong reputation in both Indian and international markets. Over its rich journey, the company has demonstrated consistent growth and expansion, cementing its position in the pharmaceutical sector.
The promoters of the company include Kaygee Investments Private Limited, with a 21.47% stake. A team of managerial promoters manage the operations of the company. They are -
- Premchand Godha
- Ajit Kumar Jain
- Pranay Godha
- Prashant Godha
- Manisha Premnath
While Ipca Laboratories may not be the largest in terms of market share or capitalization, it is still highly regarded in the market. The company is known for its innovative solutions and customer-centric approach. The registered office of Ipca Laboratories Ltd. is in Kandivli, Mumbai and the office of the registrar is in Vikhroli, Mumbai.
Ipca Laboratories Ltd. stands out as a major player in the pharmaceutical sector. It has a rich history, a robust product portfolio, and a strong market presence. Its strategic partnerships and efficient management continue to drive the company forward.
Impact of Ipca Laboratories Limited
In India and around the world, Ipca Laboratories Ltd. has had a big influence on the pharmaceutical sector. Since its founding in 1949, the company has expanded greatly. It is currently a well-known brand for creating formulations and active pharmaceutical ingredients (APIs). Rheumatology is one of the therapeutic areas in which it makes contributions. Due to this, the company has been able to play a significant role in enhancing healthcare results.The manufacture and distribution of premium APIs is one of Ipca Laboratories' main contributions. The business produces more than 80 APIs, which are utilized in manufacturing different drugs. Since they make up the active ingredients of medications, these APIs are crucial to the pharmaceutical sector.
Ipca Laboratories has also made a significant impact through its formulation business. The company produces a wide range of generic and branded formulations, including tablets and injectables. These products cater to various therapeutic areas, providing effective treatment options for patients. Ipca’s formulations are known for their efficacy and affordability, making them accessible to a broad population.
The company’s focus on research and development (R&D) has further amplified its impact. Ipca Laboratories invests significantly in R&D to develop new and improved pharmaceutical products. This investment has led to the creation of innovative therapies that address unmet medical needs. For example, Ipca’s advancements in antimalarial drugs have played a crucial role in combating malaria, which affects millions of people worldwide. The company’s R&D efforts keep it at the forefront of pharmaceutical innovation. These efforts continuously contribute to the advancement of medical science.
Ipca Laboratories’ commitment to sustainability and corporate social responsibility (CSR) also highlights its impact. The company engages in various CSR initiatives aimed at improving the quality of life in the communities where it operates. These initiatives include healthcare camps and environmental conservation efforts.
The company’s global reach further underscores its impact. Ipca Laboratories exports its products to over 120 countries, which includes highly regulated markets like the United States and Japan. This extensive global presence ensures that high-quality medications are available to patients worldwide. Ipca’s ability to meet international regulatory standards demonstrates its commitment to quality and safety. This reinforces its reputation as a reliable pharmaceutical manufacturer.
Ipca Laboratories has also played a crucial role in supporting the healthcare infrastructure in India. The company collaborates with various healthcare providers and government agencies. This helps improve access to essential medicines. These collaborations have been especially important during public health emergencies like the COVID-19 pandemic. Ipca’s timely supply of critical medications helped manage the crisis.
The financial performance and growth trajectory of Ipca Laboratories are indicative of its impact on the industry. The company has consistently achieved strong revenue growth. This is driven by its robust product portfolio and strategic market expansion. Ipca’s financial stability provides confidence to investors and stakeholders. It also enables the company to continue investing in innovation and growth.
Ipca Laboratories’ impact is also evident in its role as an employer. The company employs thousands of people, contributing to economic development and social stability. Ipca’s focus on employee development and welfare ensures that its workforce is skilled, motivated, and engaged. This commitment to human capital development is essential for the company’s long-term success and sustainability.
FAQ’s
What is the share price of Ipca Laboratories Ltd today?
Ipca Laboratories Ltd share price as on 30 Nov 2025 is ₹ 1421.0
What is the Market Cap of Ipca Laboratories Ltd?
The market cap of Ipca Laboratories Ltd stock is ₹35,417.11 Cr.
What is the PE Ratio of Ipca Laboratories Ltd?
The Price to Earnings (P/E) Ratio of Ipca Laboratories Ltd is 58.53
What is the PB Ratio of Ipca Laboratories Ltd?
The Price to Book (P/B) Ratio of Ipca Laboratories Ltd is 5.53
What is the 52 week high of Ipca Laboratories Ltd Share Price?
The 52 week high of Ipca Laboratories Ltd share price stands at ₹1,755.90
What is the 52 week low of Ipca Laboratories Ltd Share Price?
The 52 week low of Ipca Laboratories Ltd share price stands at ₹1,168.20
How can I buy shares of Ipca Laboratories Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Ipca Laboratories Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
